November 10, 2020
Amniox Launches Virtual Education and Diabetic Foot Ulcer Outreach Campaign to Support National Diabetes Month
Month-long campaign features a host of educational activities focusing on management of complex, chronic wounds resulting from diabetes
Miami, FL – November 10, 2020 – Amniox Medical, Inc. (Amniox), a TissueTech, Inc. company and pioneer in the clinical application of human birth tissue-based products, announced today that it had joined forces with key stakeholder groups around the nation who are advocating for diabetes awareness and optimal patient care, especially in chronic, debilitating conditions like late stage (Wagner Grade 3 and 4) Complex Diabetic Foot Ulcers (DFUs). Amniox has rolled out a month-long virtual campaign, #DFUAvengers, targeting health care professionals who treat patients living with chronic wounds.
Health care professionals can learn about the Neox® family of Cryopreserved Umbilical Cord Allografts at the SAWC Fall Virtual Meeting 2020 from November 4 – 6, and at the WoundCon Fall 2020 Virtual Conference and Exhibition on November 13, 2020. Neox wound allografts support regenerative healing and functional recovery for late stage and chronic wounds with higher closure rates, fewer applications, and reduced cost of care.1
People with diabetes mellitus are at substantial risk of developing a foot ulcer at some point in their lifetime. Unlike other types of deep wounds, DFUs typically exhibit delayed healing and a downstream consequence of prolonged high levels of glucose in the blood. This can trigger a wide range of molecular events leading to damage of the nerves, blood vessels, tissues, and organs. Damage to blood vessels can increase the risk of heart attack and stroke, and nerve damage can lead to eye damage or kidney damage.2
“A cornerstone of this campaign is peer-to-peer education. #DFUAvengers will afford clinicians several opportunities to learn how our cryopreserved umbilical cord allograft, Neox, is used as an adjunct therapy to expedite wound healing,” said TissueTech co-founder Amy Tseng, MBA, CEO, and President.
Please join us for a live webinar on Wednesday, November 18, 2020, from 8:30pm – 9:30pm, EST. Umbilical Cord Allograft Applications inLimb Salvagewill be presented by Jacob Wynes, DPM and Thomas Fusco, DPM, FACFAS. There is no cost to participate. Click here to register.
Amniox also proudly supports the Centers for Disease Control and Prevention’s (CDC) National Diabetes Prevention Program that addresses the increasing burden of prediabetes and type 2 diabetes in the United States. This program offers evidence-based, cost-effective interventions that help prevent type 2 diabetes. You can refer your at-risk patients to a CDC-recognized lifestyle change program proven by research to cut their risk of type 2 diabetes by more than half. Participating in this program will encourage weight loss and other healthy changes to your patients’ lifestyles, lowering their risk of type 2 diabetes, heart attack, and stroke.
For a complete schedule of #DFUAvengers virtual activities, visit our website.
About Amniox Medical, Inc.
Amniox Medical, Inc., a TissueTech, Inc. company, is a leader in the clinical application of human birth tissue-based products (amniotic membrane & umbilical cord) processed using TissueTech’s proprietary CryoTek® cryopreservation technology. Established in 2011, Amniox serves an unmet need for better surgical and therapeutic outcomes for chronic and complex wounds, orthopedics, sports medicine, spine, urology, gynecology, plastics, and general surgery. Connect with Amniox on our Website, Facebook, LinkedIn and Twitter.
About TissueTech, Inc.
TissueTech, Inc., the parent company of Amniox Medical, Inc. and BioTissue, Inc., is a scientific and market leader in the field of regenerative medicine. TissueTech manufactures a broad range of ocular, surgical, wound care, and soft tissue products that are marketed under these subsidiaries. Since the company’s inception, clinicians have performed more than 500,000 human implants of the company’s products and published more than 360 peer-reviewed studies supporting its platform technology. TissueTech is committed to an unwavering culture of integrity that places our patients’ safety and clinical outcomes above all else. Learn more at https://biotissue.com/.